Profile data is unavailable for this security.
About the company
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.
- Revenue in USD (TTM)408.81m
- Net income in USD-1.71m
- Incorporated2012
- Employees797.00
- LocationAxonics Inc26 Technology DriveIRVINE 92618United StatesUSA
- Phone+1 (949) 396-6322
- Fax+1 (949) 396-6321
- Websitehttps://www.axonics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enovis Corp | 1.91bn | -107.11m | 2.27bn | 6.55k | -- | 0.6793 | 15.72 | 1.19 | -1.96 | -1.65 | 35.01 | 59.90 | 0.3872 | 1.53 | 5.52 | 292,209.20 | -2.16 | -0.3569 | -2.37 | -0.41 | 57.30 | 48.19 | -5.57 | -1.06 | 1.08 | 0.836 | 0.2902 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
Myriad Genetics, Inc. | 802.20m | -155.20m | 2.40bn | 2.70k | -- | 3.25 | -- | 3.00 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
10X Genomics Inc | 631.73m | -239.78m | 2.41bn | 1.26k | -- | 3.33 | -- | 3.82 | -2.02 | -2.02 | 5.31 | 6.01 | 0.6583 | 2.59 | 7.06 | 501,773.60 | -24.99 | -25.52 | -28.04 | -29.05 | 64.70 | 75.88 | -37.96 | -48.53 | 4.42 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
Inari Medical Inc | 547.47m | -57.05m | 2.44bn | 1.30k | -- | 5.75 | -- | 4.46 | -0.9838 | -0.9838 | 9.43 | 7.29 | 0.9141 | 1.59 | 7.56 | 421,133.80 | -9.53 | -0.5941 | -11.39 | -0.6696 | 87.15 | 89.06 | -10.42 | -0.6295 | 1.45 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
Tandem Diabetes Care Inc | 796.00m | -136.49m | 2.74bn | 2.40k | -- | 11.69 | -- | 3.44 | -2.09 | -2.09 | 12.21 | 3.57 | 0.8449 | 2.62 | 8.09 | 331,667.50 | -14.49 | -10.08 | -18.58 | -12.23 | 49.06 | 51.77 | -17.15 | -11.59 | 2.38 | -- | 0.598 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
LivaNova PLC | 1.21bn | -16.59m | 2.92bn | 2.90k | -- | 2.35 | 97.45 | 2.42 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
Quidelortho Corp | 2.83bn | -1.86bn | 2.94bn | 7.10k | -- | 0.9255 | -- | 1.04 | -27.79 | -27.79 | 42.35 | 47.30 | 0.372 | 2.58 | 9.15 | 399,239.40 | -24.40 | 11.34 | -27.51 | 12.91 | 47.89 | 62.71 | -65.60 | 20.93 | 0.7929 | 0.7895 | 0.4469 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
Evolent Health Inc | 2.35bn | -106.20m | 3.06bn | 4.70k | -- | 2.87 | 200.10 | 1.30 | -0.9367 | -0.9367 | 20.71 | 10.79 | 0.9191 | -- | 6.55 | 500,823.00 | -2.91 | -9.60 | -3.63 | -12.59 | 18.57 | 24.50 | -3.16 | -13.66 | -- | -0.2382 | 0.326 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
Envista Holdings Corp | 2.53bn | -1.32bn | 3.24bn | 12.80k | -- | 1.09 | -- | 1.28 | -7.70 | -7.70 | 14.64 | 17.32 | 0.4207 | 4.08 | 6.37 | 197,937.50 | -21.98 | 1.94 | -26.29 | 2.34 | 54.89 | 57.65 | -52.25 | 5.29 | 1.90 | 3.92 | 0.3357 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
Neogen Corp | 924.22m | -9.42m | 3.27bn | 2.92k | -- | 1.04 | 30.44 | 3.53 | -0.0435 | -0.0435 | 4.27 | 14.51 | 0.203 | 2.85 | 5.67 | 316,839.90 | -0.207 | 1.38 | -0.214 | 1.44 | 50.19 | 48.23 | -1.02 | 4.31 | 2.59 | 1.19 | 0.2208 | 0.00 | 12.37 | 17.41 | 58.81 | -- | 50.02 | -- |
Axonics Inc | 408.81m | -1.71m | 3.56bn | 797.00 | -- | 5.52 | 327.96 | 8.71 | -0.0291 | -0.0291 | 8.11 | 12.61 | 0.5856 | 1.12 | 7.81 | 512,934.80 | -0.2451 | -12.67 | -0.2618 | -13.76 | 75.89 | 70.04 | -0.4185 | -29.68 | 7.11 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
Procept Biorobotics Corp | 176.58m | -103.71m | 3.74bn | 626.00 | -- | 14.98 | -- | 21.16 | -2.06 | -2.06 | 3.50 | 4.85 | 0.546 | 1.85 | 3.83 | 282,068.70 | -32.07 | -- | -36.52 | -- | 54.73 | -- | -58.73 | -- | 6.49 | -- | 0.1696 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
Haemonetics Corporation | 1.33bn | 114.89m | 3.99bn | 3.66k | 34.89 | 4.40 | 18.27 | 2.99 | 2.23 | 2.23 | 25.92 | 17.70 | 0.5924 | 1.87 | 7.05 | 364,751.20 | 5.10 | 5.02 | 5.74 | 6.07 | 53.58 | 51.74 | 8.61 | 8.11 | 2.33 | 60.20 | 0.5747 | 0.00 | 12.01 | 6.23 | 1.87 | 16.40 | -11.04 | -- |
Integer Holdings Corp | 1.67bn | 105.37m | 4.33bn | 10.50k | 42.36 | 2.79 | 20.71 | 2.59 | 3.05 | 3.05 | 48.27 | 46.34 | 0.5574 | 4.88 | 5.10 | 158,938.20 | 3.52 | 3.28 | 3.78 | 3.53 | 26.77 | 26.94 | 6.31 | 6.40 | 1.96 | 3.67 | 0.4215 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
ICU Medical Inc | 2.30bn | -70.79m | 4.38bn | 14.00k | -- | 2.15 | 27.91 | 1.90 | -2.92 | -2.92 | 94.90 | 83.43 | 0.5267 | 2.13 | 14.68 | 164,591.20 | -1.62 | 1.46 | -1.83 | 1.65 | 32.47 | 34.11 | -3.07 | 2.23 | 1.08 | 0.5555 | 0.4412 | 0.00 | -0.9154 | 10.04 | 60.08 | -- | -1.45 | -- |
TransMedics Group Inc | 358.76m | 3.00m | 4.64bn | 584.00 | 3,368.15 | 24.38 | 266.46 | 12.92 | 0.0413 | 0.0413 | 10.61 | 5.70 | 0.4952 | 3.56 | 5.58 | 614,313.40 | 0.4141 | -16.08 | 0.4403 | -17.95 | 60.71 | 65.37 | 0.8362 | -40.47 | 8.48 | -- | 0.7278 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.90m | 9.60% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.68m | 7.21% |
Alpine Associates Management, Inc.as of 30 Jun 2024 | 2.11m | 4.13% |
Fidelity Investments Canada ULCas of 31 Mar 2024 | 1.72m | 3.37% |
Mackenzie Financial Corp.as of 31 Mar 2024 | 1.27m | 2.48% |
Kryger Capital Ltd.as of 30 Jun 2024 | 1.22m | 2.39% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.19m | 2.34% |
Millennium Management LLCas of 31 Mar 2024 | 1.19m | 2.33% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.19m | 2.32% |
Magnetar Financial LLCas of 31 Mar 2024 | 1.15m | 2.25% |